Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -472.20% | 37.92% | -39.15% | 34.68% | 95.64% |
| Total Depreciation and Amortization | -25.69% | 29.94% | -33.33% | -22.71% | -53.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,835.96% | -149.56% | 1,249.20% | -120.36% | -87.32% |
| Change in Net Operating Assets | -463.16% | 153.42% | -18.40% | 91.47% | -120.28% |
| Cash from Operations | -1,281.38% | 88.07% | -21.43% | 35.83% | 89.89% |
| Capital Expenditure | -- | 100.00% | -283.33% | -- | 95.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,313.85% | 226.36% | 102.78% | -25.00% | -92.32% |
| Cash from Investing | 2,084.29% | 226.28% | 102.65% | 51.34% | -90.96% |
| Total Debt Issued | -- | -- | -10.21% | 9.32% | -- |
| Total Debt Repaid | -- | -127.99% | 55.06% | 48.73% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -127.99% | 23.65% | 103.18% | 108.25% |
| Foreign Exchange rate Adjustments | 226.80% | -200.93% | 184.58% | -6,200.00% | -188.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 546.26% | 143.68% | 67.44% | 37.67% | -485.24% |